Oncology

News

Syndax gets FDA okay for first-in-class leukaemia drug

A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.

News

MSD joins PD-1/VEGF push in cancer with LaNova deal

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy.

News

Bone marrow aspirate showing the histologic correlate of multiple myeloma under the microscope, H&E stain

GSK hails survival data with revived myeloma drug Blenrep

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached stat

News

BioNTech buys Biotheus and its Keytruda rival for $950m

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.

News

Scrabble letters spelling out 'Learn from failure'

Daiichi and AZ pull Dato-DXd filing with FDA and try again

Nine months after filing their TROP2-directed antibody-drug conjugate Dato-DXd for a lung cancer indication with the FDA, Daiichi Sankyo and AstraZeneca have pulled the submission.

News

window into laboratory with scientist hard at work

Autolus bags FDA approval for leukaemia cell therapy

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL).

Syndax gets FDA okay for first-in-class leukaemia drug

MSD joins PD-1/VEGF push in cancer with LaNova deal

GSK hails survival data with revived myeloma drug Blenrep

BioNTech buys Biotheus and its Keytruda rival for $950m

Daiichi and AZ pull Dato-DXd filing with FDA and try again

Autolus bags FDA approval for leukaemia cell therapy

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks